Viatris | VTRS - Operating Expenses


Viatris reported $3.53B in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Celltrion KRW 724.99B 6B Sep/2025
Cspc Pharmaceutical CNY 5.4B 298.41M Sep/2025
Deva Holding AS TRY 1.35B 178.26M Sep/2023
Dianthus Therapeutics USD 40.68M 5.56M Sep/2025
Divis Laboratories Ltd INR 18.32B 1.08B Dec/2025
Kangmei Pharma CNY 1.39B 144.29M Sep/2025
Knight Therapeutics CAD 89.06M 2.02M Sep/2024
Laboratorios Farma EUR 313.62M 17.98M Dec/2023
Malin Corporation EUR 1.1M 400K Dec/2024
Medical Developments International AUD 10.02M 9.78M Jun/2025
Neuren Pharmaceuticals AUD 8.69M 8.72M Jun/2025
Organigram Holdings CAD 108.11M 17.03M Sep/2025
Ovoca Bio EUR 5.65M 3.45M Jun/2022
Pharma Mar EUR 39.62M 7.34M Sep/2025
Qiagen NV USD 418.54M 23.25M Dec/2025
Sartorius EUR 693.1M 29.4M Sep/2025
Sino Biopharmaceutical CNY 12.39B 1.26B Jun/2025
Tilray USD 237.52M 17.34M Sep/2025
Viatris USD 3.53B 128.7M Sep/2025
Zz Pientze Pharmaceu CNY 1.55B 129.66M Sep/2025